It was the final day of the American Association of Neurology (ANA) conference yesterday and prion diseases took center stage. John Collinge, the only prominent British presence at the conference, set the ball rolling with insights into the potential treatment of CJD with anti-PrP monoclonal antibodies.
But it wasn’t the day for traditional prion diseases as speaker after speaker took the stage to claim prion pathology for other neurodegenerative diseases; and not just Parkinson’s disease (PD) or multiple system atrophy MSA. Neil Cashman gave an excellent talk on propagated misfolding (what a buzzword) in SOD1 motor neurone disease (MND) and also hinted at potential treatment with antibodies. Marc Diamond looked at tau prions and how their spread may be tracked by FRET-based biosensor cell assay (a mouthful).
J Paul Taylor looked at the role of RNA binding proteins (RBPs) in several neuodegenerative diseases including MND and frontotemporal dementia (FTD). And yes, these RBPs show prion-like activity.
There was an interesting case-based session on chronic traumatic encephalopathy (CTE). This was led by Jeffrey Kutcher, possibly the foremost authority on this neurodegenerative condition. I learnt that CTE is a post-mortem diagnosis and that in life the diagnosis should be restricted to traumatic encephalopathy syndrome (TES).
The day was rounded up by two excellent debates on stroke treatment. Marc Chimowitz took on Graeme Hankey on the comparative advantages of dual and single antiplatelets for secondary stroke prevention; it was the battle of the lumpers versus the splitters and it was probably a draw. Jeffrey Saver was however the clear winner over Colin Derdeyn by arguing for the combined use of thrombolysis and thrombectomy, rather than thromectomy alone.
Its day 3 about to start at the American Neurological Association (ANA) annual conference. As a follow up tp my previous posts, this is a quick take on 6 new buzzwords for me from day 2. These are at the cutting edge of neurology
Metagenomic deep sequencing. This promises to solve the pervasive problem of undiagnosed encephalitis and meningitis. James Wilson’s talk was heavy; here is a link to an abstract which hopefully simplifies things
Before day 2 commences, a quick word on a wonderful symposium on Multiple Sclerosis (MS).
MS epidemiologists and researchers dissected the topic Causes/Triggers of MS. Speakers were David Hafler, Alberto Aschiero, Lisa Barcellos and Larry Steinman. And the top 6 are
Vitamin D deficiency
Overweight in early age
High salt intake
I suggested to David we should only be looking for correlation rather than causation (an idea I picked up from a great book Big Data).
He strongly disagreed! He believes genome wide association studies (GAS) have confirmed the cause for MS. I think the search for a definite cause is probably futile but we define cause flexibly. Alberto made the point that even if all the known risk factors were eliminated, MS will still be very prevalent
If you missed my blog on Klotho, you should check it out first before continuing. Below are the other four new things I learnt on the first full day of the American Neurological Association meeting, Chicago 2015:
BIN1 is the second commonest monogenic genetic cause of Alzheimer’s disease (AD). And I never even heard of BIN1 before today. Work by Erik Roberson
LINGO 1 is probably the only gene established to be associated with Essential Tremor (ET). Presentation by Ludy Shih
FLAIR* MRI imaging of Multiple Sclerosis (MS) shows either a centripetal or centrifugal pattern of inflammatory lesions with serious implications to prognosis. Work by Daniel Reich of NINDS
Diabetic peripheral neuropathy is a result of the metabolic syndrome; research by Lucy Hinder in mice suggests this is potentially reversible
It’s the American Neurological Association‘s 140th Annual meeting in Chicago this weekend and my first attendance. It is holding at the grand Marriott Hotel on The Magnificent Mile.
It is a rigorously academic meeting and the highlight for me on the first day is the presentation by the Gross Awardee, Dena Dubal, on the longevity protein Klotho. Heterozygote variants of its gene appears to confer longevity, enhance cognition, and prevent neurodegenerative diseases. It’s almost too good to be true- but her research is practically faultless.
‘What happens if one has the homozygote variant?’ she was asked during Q and A. Unfortunately and paradoxically a double dose of the variant results in faster aging!
Her lab’s site has more to say on her research into aging and neuroscience-well worth bookmarking.
Quite a few neurological disorders remain mysteries even when we know so much about them. Parkinson’s diseases (PD) is one of them. Dopamine deficiency is the established final common pathway, but why this deficiency presents in different ways is unclear. PD variants such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and Lewy body disease (LDB) have distinct clinical features to confound any common cause. What then causes dopamine deficiency in the first place?
Clearly we can’t recommend vagotomy to our at-risk PD patients, and neither can we recommend gout! Yes, studies have suggested that PD patients have a low uric acid level, and this predates the disease onset. Another study takes things further to suggest that uric acid is neuroprotective because of its antioxidant effect. This long list of PubMed abstracts shows the proliferating research into uric acid.
And finally, again from the Annals of Neurology, is a paper reporting increased creativity in people with PD on dopamine replacement treatment. The study compares people with PD on treatment to control subjects. It is however not clear if the creativity is a feature of PD, or of its treatment.
Gluten neurology is a controversial issue, to say the least! The heated debates between Sheffield and Nottingham may lie in the fog of history, but the issue simmers just below the surface. Gluten sensitivity, or coeliac disease, is a big time player in other body systems, but its neurological manifestations are clouded in mystery.